tbuckley/cabot-search huggingface dataset:
Risk of recurrence after endoscopic resection of early colorectal cancer with positive margins
Authors: Je-Wook Shin, Kyung Han, Jong Hyun, Sang Lee, Bun Kim, Chang Hong, Byung Kim, Dae Sohn, Hee Chang, Min Kim, Sung Park, Jae Oh
Journal: Endoscopy (2017)

Additional surgery is recommended if an endoscopically resected T1 colorectal cancer (CRC) specimen shows a positive resection margin. We aimed to investigate the significance of a positive resection margin in endoscopically resected T1 CRC.We enrolled 265 patients with T1 CRC who underwent endoscopic resection between January 2001 and December 2016. The inclusion criteria were: 1) complete resection by endoscopy, and 2) pathology of a positive margin. Among the 265 patients, 213 underwent additional surgery and 52 did not. In the additional surgery group, various clinicopathological factors were evaluated with respect to the presence or absence of residual tumor. The follow-up results were assessed in the group that did not undergo additional surgery.In the 213 patients who underwent additional surgery, residual tumor was detected in 13 patients (6.1 %), and none of the clinicopathological factors was significantly associated with the presence of residual tumor. Among the 52 patients who did not undergo additional surgery, recurrence was detected in 4 (7.7 %), and all 4 underwent salvage surgery. Among these four patients, three had no risk factors for lymph node metastasis and recurrence was at the previous resection site; pathology was high grade dysplasia, rpT3N0M0, and rpT1N0M0, respectively.A positive resection margin in endoscopically resected T1 CRC is related to a relatively low incidence of residual tumor (6.1 %). Although current guidelines recommend additional surgery for such cases, surveillance and timely salvage surgery could be another option in selected cases.
GENE-52. EPIGENOMIC GLIOMA SUBTYPE EVALUATION ACROSS 31 TUMOR TYPES
Authors: Maritza Mosella, Thais Sarraf, Tathiane Malta, Tiago Chedraoui, Houtan Noushmehr, Ana Valéria Castro
Journal: Neuro-Oncology (2017)

A recent molecular low and high grade glioma (G) epigenomic profiling has uncovered clinically relevant subtypes that refined the existent glioma classification (based on IDH and codeletion status) into seven discrete groups with distinct clinicopathological and prognostic outcomes. IDH-mutants gliomas were further classified in G-CIMP-low and -high or codel and IDH-wildtype (wt) in classic-like, mesenchymal-like, and IDH-wt-K3 (LGm6-GBM, and PA-like subgroups). Epigenetic signatures defined prognostic outcome among gliomas. We hypothesized that the glioma methylome-based signatures may also classify other tumors into discrete subgroups with prognostic relevance. Utilizing the Random Forest method, we analyzed the 450K-platform-based methylome of 7,656 samples across 31 primary tumor types (pan-cancer) and classified those tumors according to the glioma methylome-based signatures. The majority of cancer samples fell into the glioma IDH-wt-like group (98.5%). Within it, glioma-IDH-wt-K3-like subtype (n=3147) had a significant better overall survival (OS) than glioma-mesenchymal-like (n=3670) and glioma-classic-like (n=658) subgroups (p=2e-16), resembling the behavior of the correspondent glioma subtypes. In contrast to gliomas, in which G-CIMP-low subtype had poorer OS than G-CIMP-high and codels, no significant differences in OS were found among the IDH-mutant subtypes. In the IDH-mut-like pan-cancer group, G-CIMP-high/low subtypes and glioma-codel-like presented none or only 3% IDH mutations, respectively. The pan-cancer glioma-methylome signatures revealed that most of human tumors fall into the glioma IDH-wt subtype with similar OS pattern as in gliomas. Among the IDH-mutant-like pan-cancer subtype, the OS were similar among subgroups. IDH was not mutated in the CIMP-like cancer group, suggesting that although these tumors resemble the G-CIMP molecular profile, the molecular mechanisms that may drive the epigenetic phenotype and OS in those tumors are yet to be determined.
Legionelosis en Europa asociada a los viajes: 1997 y 1998
Authors: E Slaymaker, C Joseph, C L R Bartlett
Journal: Eurosurveillance (1999)

La Red de Vigilancia Europea de la legionelosis asociada a viajes fue puesta en marcha en 1987 por el Grupo de Trabajo Europeo de infecciones por Legionella (European Working Group for Legionella Infections, EWGLI), con el fin de identificar casos de infeccion por legionella en personas de regreso de viajes, asi como detectar brotes y agrupaciones de casos de legionelosis. En un principio, la red fue coordinada por el Instituto Sueco para el Control de Enfermedades Infecciosas (SIIDC) de Estocolmo, que conto con la financiacion de la Organizacion Mundial de la Salud (OMS). En 1993, se traslado a su sede actual en el Servicio de Laboratorio de Salud Publica (PHLS, Public Health Laboratory Service) del Centro de Vigilancia de Enfermedades Transmisibles (CDSC, Communicable Disease Surveillance Centre) de Londres, cambio que coincidio con el inicio de la financiacion por parte de la Direccion General V de la Comision Europea.
The Genotype–Phenotype Relationships in the Light of Natural Selection
Authors: Han Chen, Chung-I Wu, Xionglei He
Journal: Molecular Biology and Evolution (2017)

Although any genotype-phenotype relationships are a result of evolution, little is known about how natural selection and neutral drift, two distinct driving forces of evolution, operate to shape the relationships. By analyzing ∼500 yeast quantitative traits, we reveal a basic "supervisor-worker" gene architecture underlying a trait. Supervisors are often identified by "perturbational" approaches (such as gene deletion), whereas workers, which usually show small and statistically insignificant deletion effects, are tracked primarily by "observational" approaches that examine the correlation between gene activity and trait value across a number of conditions. Accordingly, supervisors provide most of the genetic understandings of the trait whereas workers provide rich mechanistic understandings. Further analyses suggest that most observed supervisor-worker interactions may evolve largely neutrally, resulting in pervasive between-worker epistasis that suppresses the tractability of workers. In contrast, a fraction of supervisors are recruited/maintained by natural selection to build worker co-expression, boosting the tractability of workers. Thus, by revealing a supervisor-worker gene architecture underlying complex traits, the opposite roles of natural selection versus neutral drift in shaping the gene architecture, and the complementary strengths of the perturbational and observational research strategies in characterizing the gene architecture, this study may lay a new conceptual foundation for understanding the molecular basis of complex traits.
P3.09-001 The Dosimetric Advantages of Intensity Modulated Proton Therapy (IMPT) for Mesothelioma after Pleurectomy/Decortication
Authors: J. Rwigema, W. Liu, M. Patel, J. Archuleta, H. Ross, S. Beamer, T. Sio
Journal: Journal of Thoracic Oncology (2017)
TMOD-41. TWO NOVEL SETS OF PATIENT DERIVED ORTHOTOPIC XENOGRAFT MOUSE MODELS (PDOX) ESTABLISHED FROM MATCHING PRIMARY AND RECURRENT PEDIATRIC BRAIN TUMORS
Authors: Yuchen Du, Frank Braun, Huiyuan Zhang, Lin Qi, Holly Lindsay, Mari Kogiso, Sibo Zhao, Marcel Kool, Clifford Stephan, Xiao-Nan Li
Journal: Neuro-Oncology (2017)

It is imperative to gain a better understanding of biological changes that occur during tumor progression/evolution/recurrence to facilitated the development of new anti-recurrent therapies. Single patient tumor cells were immediately dissociated, cultured in vitro or/and transplanted into mouse brains corresponding to the patient’s tumor location. Whole genome DNA methylation, transcriptomic profiling and RNA sequencing were performed in addition to immunohistological phenotypes. Standard therapies which follow clinical regimen were conducted as well in tumor xenografts. We successfully established two sets of matched primary and recurrent PDOX models. Compared with the primary tumors, the tumor-take rate of the recurrent tumors (obtained 9 months after chemo-therapy and stem cell rescue) with shortened tumor onset time increased from 70% of primary tumor 19850PNET to 100% of recurrent 22909PNET (piece#1) and 23542PNET (piece#2) with significantly shorten animal survival times (4-5 months to 2-3 months). In the second set of PDOX models derived a low grade ganglioglioma (100815GGG) and a matching recurrent glioblastoma (104488GBM), progressive phenotypes with decreased tumor onset time (from 5 months to 3 months) was also noted. RNA sequencing reveals preserved and newly mutated genes in recurrent tumors. High-throughput drug screening using cultured patient tumor cells 100815GGG and 104488GBM discovered a shared and a diverse panel of therapeutic targets that could be selected further for in vivo drug treatment in future. Standard chemo-therapy were conducted in xenografts for primary 19850PNET and recurrent 23542PNET tumor. Chemo-drug administration significantly extend survival time of recurrent tumor in contrast to primary tumor. Molecular phenotypes such as genomic methylation and transcriptome profile are underway. Two sets of matched primary and recurrent pediatric brain tumors, PNET/PNET and GGG/GBM, were successfully established in pediatric orthotopic mice tumor models (PDOXs) providing clinically-relevant and biologically-accurate animal model systems for development of novel therapeutic targets.
A robust strategy for preparation of sequential stimuli-responsive block copolymer prodrugs via thiolactone chemistry to overcome multiple anticancer drug delivery barriers
Authors: Wendong Ke, Wei Yin, Zengshi Zha, Jean Felix Mukerabigwi, Weijian Chen, Yuheng Wang, Chuanxin He, Zhishen Ge
Journal: Biomaterials (2017)
TMIC-27. SHEAR STRESS AND INTERSTITIAL FLUID FLOW MODULATE GLIAL CELL-MEDIATED CHEMOTAXIS OF GLIOMA
Authors: Chase Cornelison, Jessica Yuan, Caroline Brennan, Jennifer Munson
Journal: Neuro-Oncology (2017)

INTRODUCTIONGlioblastoma is characterized by invasion into surrounding parenchyma. At these tumor-parenchyma interfaces, heightened interstitial fluid flow can lead to increases in cancer cell invasion. In other tissues, interstitial fluid flow and increased shear stress alters stromal cell behaviors and activation, leading to increased cancer cell invasion and worsened disease. Here we hypothesized that interstitial fluid flow and shear stress stimulate astrocytes and microglia in the brain to enhance glioma cell invasion.
OA 03.03 Phase II Trial of Cetuximab and Chemotherapy Followed by Surgical Resection for Locally Advanced Thymoma
Authors: J. Huang, D. Raz, M. Cristea, K.S. Tan, K. Deonaraine, A. Starr, W. Travis, M. Ginsberg, D. Jones, V. Rusch, M. Kris, G. Riely
Journal: Journal of Thoracic Oncology (2017)
MA 15.01 LungBEAM: A Prospective Multicenter Trial to Monitor EGFR Mutations Using BEAMing Technology in Stage IV NSCLC Patients
Authors: P. Garrido, E. Felip, L. Paz-Ares, M. Majem, T. Morán, J. Bosch, M. Trigo, R. García Campelo, J.L. González-Larriba, J.M. Sánchez-Torres, D. Isla, N. Viñolas, C. Camps, A. Insa, Ó. Juan, B. Massuti, A. Paredes, A. Artal Cortes, M. López-Brea, J. Palacios
Journal: Journal of Thoracic Oncology (2017)
P3.05-006 Integrated Genomic Analysis to Assess the Molecular Signature of Japanese Patients with Non-Small Cell Lung Cancer
Authors: M. Isaka, M. Serizawa, T. Nagashima, S. Ohnami, K. Ohshima, K. Urakami, H. Kojima, S. Takahashi, A. Ono, T. Sugino, T. Takahashi, Y. Ohde, M. Kusuhara, K. Yamaguchi
Journal: Journal of Thoracic Oncology (2017)
Powerful partnerships
Authors: M. Graham, J. Carney
Journal: BMJ (1998)

Our work is based on the belief that every partnership has the potential to be extremely powerful. Maximising this potency comes primarily through knowing each other's values and goals, how you work best, how you learn best, your strengths and key skills, and those situations or behaviours that cause the greatest pressure. In learning about ourselves, we open ourselves to learning about others, creating an environment of openness, curiosity, understanding, and warmth. Partnership is a word used so often that it is easy to lose a sense of what it means - a joint business venture between two or more people. The modern partnership needs an infrastructure that is flexible enough to adapt to the perpetual change of the modern business environment, and to fulfil the ambitions of the individuals within it.

### Quick self audit

These are exercises you can do to clarify what matters to you:

When partnerships get strained, what is happening? People feel too overloaded to be able to look for solutions, and issues that were previously unresolved have come to boiling point. Partnership between general practitioners can be even more pressurised than other business partnerships if all-knowing doctors, superhuman in their ability to deal with suffering, carry that attitude into the management of their practice.

Our approach is based on research we conducted among 35 London practices …
P2.03b-098 Comparison of Digital PCR, Ion Proton with ARMS-PCR in Tumor Tissue and Plasma of NSCLC Patients
Authors: Jincui Gu, Wanchun Zang, Bing Liu, Lixia Huang, Xia Li, Ran Ding, Shaoli Li, Xuehong Meng, Zhi Jiang, Yanbin Zhou
Journal: Journal of Thoracic Oncology (2017)
NIMG-39. PATTERNS OF INTERSECTIONAL TUMOUR VOLUME IN T2-WEIGHTED MRI AND 18F-FET PET CORRELATE WITH OUTCOME IN GLIOBLASTOMA
Authors: Bogdana Suchorska, Marketa Sosnova, Marcus Unterrainer, Annamaria Biczok, Peter Bartenstein, Nathalie Albert, Joerg-Christian Tonn
Journal: Neuro-Oncology (2017)

Tumour volume of glioblastoma (GB) obtained by 18F-FET PET and conventional MRI T2 images differ in many cases. Aim of the present study was to define tumour volume in newly diagnosed GB on both T2 and 18F-FET PET and to determine different volumetric intersection patterns and their association with prognosis. T2 and 18F-FET PET volumes were simultaneously assessed prior to any further procedure. Intersection patterns were defined according to both imaging modalities following tumour T2-based and 18F-FET PET volume delineation. Histology and molecular characteristics were acquired via biopsy or surgery in all patients. All patients were intended to receive adjuvant radio-chemotherapy. The obtained intersection volume patterns were correlated with progression-free (PFS) and overall survival (OS). In 65 de-novo WHO IV patients, four different volumetric patterns could be identified. In pattern 1, (46.2% of all patients), 18F-FET-volume was almost completely enclosed within a larger T2-volume (ratio of overlap T2 / 18F-FET was < 0.5). In pattern 2 (18.4%), the T2-volume was embedded in a larger 18F-FET-volume (ratio of overlap T2 /18F-FET was > 1.5). In pattern 3 (20%), the volumes of both modalities showed a high overlap (overlap > 50%) and in pattern 4 (15.4%), the volumes of both modalities showed a low overlap (overlap areas were < 50%). There was no correlation between MGMT promotor methylation and the intersection patterns. With 15.2 compared to 12.5 months, patients with pattern 1 (18F-FET-volume within T2-volume) had significantly longer OS (log-rank p=0.024) times compared to patients with other patterns. Multivariate analysis has shown lower age, methylated MGMT promotor and pattern 1 to be independently associated with improved OS. Intersectional tumour volumes in GB as defined by 18F-FET PET and T2 correlate with outcome: patients with a 18F-FET-volume within T2-lesion show significantly longer OS.
Association of Genetic Risk for Schizophrenia and Bipolar Disorder With Infant Neuromotor Development
Authors: Fadila Serdarevic, Philip R. Jansen, Akhgar Ghassabian, Tonya White, Vincent W. V. Jaddoe, Danielle Posthuma, Henning Tiemeier
Journal: JAMA Psychiatry (2017)

This study uses data from the population-based Generation R Study of Rotterdam, the Netherlands, to assess an association of genetic risk for schizophrenia and bipolar disorder with infant neuromotor development.
DRES-16. PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOMA MODELS
Authors: Fumi Higuchi, Hiroaki Wakimoto, Daniel Cahill
Journal: Neuro-Oncology (2017)

Mismatch repair (MMR) deficiency through MSH6 inactivation has been identified in approximately 30% of recurrent gliomas. This MMR deficiency represents a key molecular mechanism of acquired resistance to the alkylating chemotherapeutic agent temozolomide (TMZ). In addition, it is known that poly(ADP-ribose) polymerase-1 (PARP) plays important roles in DNA damage recognition, signaling and repair. The potentiation of TMZ-induced cytotoxicity by PARP inhibitors in cancer cells has been well-established. Here, we investigated whether PARP inhibitors could restore chemosensitivity of MSH6-deficient chemoresistant gliomas to TMZ. We determined the efficacy of TMZ treatment with PARP inhibitors veliparib and olaparib in glioma cell lines and patient-derived glioblastoma neurosphere lines. We engineered these lines to knockdown MSH6 expression, resulting in acquired MMR-deficient resistance to TMZ. Using these isogenic MSH6-deficient glioma xenografts, we tested the in vivo efficacy of veliparib in combination with TMZ, compared to TMZ monotherapy. We found that combination with veliparib restores TMZ sensitivity in otherwise TMZ-resistant MSH6-deficient glioma cells in vitro. As evidence distinct from the known combination effect, we found that relatively low concentrations of PARP inhibitor treatment (which has no detectable effect as a single agent) were sufficient to resensitize MMR-deficient cells, whereas only subtle combination effects are seen control isogenic MMR-proficient cells at the same concentration of PARP inhibitors. In vivo experiments examining xenograft growth in mice treated with TMZ in-combination with veliparib significantly delays tumors outgrowth. Furthermore, the combination of TMZ with veliparib resulted in an extension of survival, compared with TMZ alone in an orthotopic GBM model. Combination of TMZ with PARP inhibitor treatment is especially effective at restoring chemosensitivity in MSH6-inactivated, MMR-deficient gliomas. We propose that combination strategies to target this genetically-defined subgroup of recurrent gliomas be evaluated in clinical trials.
P1.09-009 Evaluation of a Combined MicroRNA-Clinical Score as Prognostic Factor for Malignant Pleural Mesothelioma
Authors: M. Kirschner, B. Vrugt, M. Friess, M. Meerang, P. Wild, N. Van Zandwijk, G. Reid, W. Weder, I. Opitz
Journal: Journal of Thoracic Oncology (2017)
Evaluación de la vigilancia de las enfermedades meningocócicas en Europa
Authors: C Trotter, S Samuelsson, A Perrocheau, S de Greeff, H de Melker, S Heuberger, M Ramsay
Journal: Eurosurveillance (2005)

En la mayoria de los paises, la vigilancia de las enfermedades meningococicas esta basada en una combinacion de sistemas de declaracion obligatoria y de notificacion por los laboratorios, considerandose que ambos infraestiman el peso de la enfermedad. La incidencia de las enfermedades meningococicas varia entre los paises de Europa, y aunque existen muchas razones para explicar esto, es importante cuantificar el grado de sub-evaluacion para poder validar las comparaciones internacionales. Presentamos aqui una revision de las publicaciones sobre la evaluacion de las enfermedades meningococicas en Europa y sobre los metodos disponibles para estimar el grado de sub-notificacion. Encontramos que la sensibilidad de los sistemas de vigilancia varia entre los paises y en el tiempo, con rangos entre el 40% hasta el 96%. Se identificaron cinco metodos apropiados para llevar a cabo estudios de evaluacion, desde simples encuestas comparativas hasta tecnicas mas complicadas como la captura-recaptura y los analisis de regresion. Estos estudios pueden ser utilizados para identificar los puntos debiles y los sesgos de los datos de vigilancia y facilitar la mejora de estos sistemas. Tambien estos resultados son relevantes para la vigilancia de otras enfermedades trasmisibles, particularmente aquellas con menos mortalidad y mas escaso impacto publico que las enfermedades meningococicas y para las cuales seria util una evaluacion.
P2.15-002 Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC): An Experience From Eastern Indian Hospital
Authors: P. Mohapatra, S. Patra, S. Bhuniya, M. Panigrahi, P. Mishra, S. Purkait, S. Mohakud, S. Naik, S. Sahoo, S. Jagaty, S. Mohankudo, Y. Dhanurdhar, S. Das Majumdar, M. Kar
Journal: Journal of Thoracic Oncology (2017)
Annals Graphic Medicine - The “Problem” List
Authors: Kyle Burch
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 November 2017Annals Graphic Medicine - The “Problem” ListFREEKyle Burch, BAKyle Burch, BAFrom Marlton, New JerseySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G17-0007 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Jorge ScheirerChief Medical Information Officer, Tower Health System, Reading, PA7 November 2017 Unrealistic scenario While the comedy of errors depicted in the cartoon is plausible, our ED docs eschew adding problems to the problem list. Author, Article, and Disclosure InformationAffiliations: From Marlton, New JerseyDisclosures: The author has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G17-0007.Author/Illustrator Information: Kyle Burch, MD, is an emergency medicine resident at Christiana Care in Newark, Delaware (e-mail, Kyle.[email protected]org). His clinical interests are in emergency medicine, prehospital emergency care, and patient safety.Author Contributions: Conception and design: K. Burch.Drafting of the article: K. Burch.Final approval of the article: K. Burch.Administrative, technical, or logistic support: K. Burch.Collection and assembly of data: K. Burch. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 November 2017Volume 167, Issue 9Page: W47-W52KeywordsConflicts of interestDisclosureEmergency medicinePatientsSafety ePublished: 7 November 2017 Issue Published: 7 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Towards the new frontier
Authors: Fiona Godlee
Journal: BMJ (2017)

The BMJ Anyone working in healthcare will be feeling the pressure of rising demand and limited resources.Being asked to rethink how you do things may be the last straw.But this is what the sustainability and transformation partnerships (STPs) are asking clinicians in England to do.So far the outcome has been mixed at best.As Jennifer Richardson reports this week (doi:10.1136/bmj.j5130), the prevailing view among hospital doctors is unengaged and unenthusiastic, with many who responded to a recent survey doubting the motives behind STPs and their likelihood of success.